78 related articles for article (PubMed ID: 1789328)
1. [Medium-weight molecules in the blood serum of patients with hyperplastic processes in the endometrium and benign and malignant ovarian tumors].
Nikolaenkova VA; Alenina TV; Sterliagova LI
Akush Ginekol (Mosk); 1991 Oct; (10):56-8. PubMed ID: 1789328
[TBL] [Abstract][Full Text] [Related]
2. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
3. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
van der Zee AG; de Cuyper EM; Limburg PC; de Bruijn HW; Hollema H; Bijzet J; Krans M; de Vries EG
Cancer; 1995 Feb; 75(4):1004-9. PubMed ID: 7842401
[TBL] [Abstract][Full Text] [Related]
4. Elevated progesterone levels in serum and ovarian venous blood in patients with ovarian tumors.
Heinonen PK; Koivula T; Pystynen P
Acta Obstet Gynecol Scand; 1985; 64(8):649-52. PubMed ID: 3832755
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
6. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
[TBL] [Abstract][Full Text] [Related]
7. [Content of middle molecular mass peptides in the blood of patients with ovarian tumor at the time of surgical treatment].
Temchenko OI
Klin Khir; 1998; (2):52-3. PubMed ID: 9615097
[No Abstract] [Full Text] [Related]
8. A new approach for identifying patients with ovarian epithelial neoplasms based on high-resolution mass spectrometry.
Silva EG; Lopez PR; Atkinson EN; Fente CA
Am J Clin Pathol; 2010 Dec; 134(6):903-9. PubMed ID: 21088153
[TBL] [Abstract][Full Text] [Related]
9. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
10. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
11. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.
Autio-Harmainen H; Karttunen T; Hurskainen T; Höyhtyä M; Kauppila A; Tryggvason K
Lab Invest; 1993 Sep; 69(3):312-21. PubMed ID: 8377473
[TBL] [Abstract][Full Text] [Related]
12. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital of eastern India.
Mondal SK; Banyopadhyay R; Nag DR; Roychowdhury S; Mondal PK; Sinha SK
J Cancer Res Ther; 2011; 7(4):433-7. PubMed ID: 22269405
[TBL] [Abstract][Full Text] [Related]
13. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
[TBL] [Abstract][Full Text] [Related]
14. [The characteristics of the phospholipid spectrum of the blood serum and of the erythrocyte membranes in patients with hyperplastic processes of the endometrium and cancer of the corpus uteri].
Makarov OV; Mazurovskaia LV; Marchenko LF; Kosetskiĭ VN
Akush Ginekol (Mosk); 1992; (8-12):49-50. PubMed ID: 1292364
[No Abstract] [Full Text] [Related]
15. Histologic grading and morphologic changes of significance in the treatment of semi-malignant and malignant ovarian tumors.
Woodruff JD; Julian CG
Proc Natl Cancer Conf; 1970; 6():347-51. PubMed ID: 5458103
[No Abstract] [Full Text] [Related]
16. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
17. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
18. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
20. Serum tumour necrosis factor alpha levels in benign and malignant lesions of the endometrium in postmenopausal women. A preliminary study.
Shaarawy M; Abdel-Aziz O
Acta Oncol; 1992; 31(4):417-20. PubMed ID: 1632976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
